1.12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy

Mind Medicine Australia

Content provided by Deborah Roberts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Deborah Roberts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

3y ago 1:06:24

MP3•Episode home

Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways.

COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD). They have 22 trials running through the US and Europe for TRD.

In this episode:

Personal journey and battles with anxiety, and seeking psychiatric help
The subjective experience of psilocybin and impact of emotional processing and cognitive function
Birth of COMPASS
The current landscape of the research
Models for therapies and how they can scale
Research questions that need to be addressed
COMPASS decision to patent psilocybin (and what this means for its scientific exploration)
Rescheduling psilocybin

Links:

COMPASS Pathways

Support the podcast:

Support the podcast (Patreon)

Support the mission:

Mind Medicine Australia

Donate to Mind Medicine Australia

Join a local chapter

Support this show http://supporter.acast.com/mind-medicine-australia.

Become a member at https://plus.acast.com/s/mind-medicine-australia.

Hosted on Acast. See acast.com/privacy for more information.

45 episodes

#Fitness #Mental Health #Alternative Health #Psychology #Psychiatry #Neuroscience #Mental Illness #Science #Medicine #Deborah Roberts #Psychedelic #Therapy #Wellbeing #Wellness #Lived Experience